[
  {
    "ts": null,
    "headline": "Incyte Announces FDA Approval of Zynyz速 (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States",
    "summary": "WILMINGTON, Del., May 15, 2025--FDA Approves Zynyz (retifanlimab-dlwr) the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States",
    "url": "https://finnhub.io/api/news?id=8cd3071f008ddbc4838e29bf87be3c2d463b892cf2a8548dcfae6b39ce1c0579",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747333800,
      "headline": "Incyte Announces FDA Approval of Zynyz速 (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States",
      "id": 134484051,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "WILMINGTON, Del., May 15, 2025--FDA Approves Zynyz (retifanlimab-dlwr) the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States",
      "url": "https://finnhub.io/api/news?id=8cd3071f008ddbc4838e29bf87be3c2d463b892cf2a8548dcfae6b39ce1c0579"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Corp. stock underperforms Thursday when compared to competitors despite daily gains",
    "summary": "Incyte Corp. stock underperforms Thursday when compared to competitors despite daily gains",
    "url": "https://finnhub.io/api/news?id=7770689db9d5f1b3fd71d23d93d0d26cbe0c54b63c076c7b982e981518d09804",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747329360,
      "headline": "Incyte Corp. stock underperforms Thursday when compared to competitors despite daily gains",
      "id": 134550354,
      "image": "",
      "related": "INCY",
      "source": "MarketWatch",
      "summary": "Incyte Corp. stock underperforms Thursday when compared to competitors despite daily gains",
      "url": "https://finnhub.io/api/news?id=7770689db9d5f1b3fd71d23d93d0d26cbe0c54b63c076c7b982e981518d09804"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Announces FDA Approval Of Zynyz For Treatment Of Advanced Anal Cancer",
    "summary": "Incyte Corp: * INCYTE ANNOUNCES FDA APPROVAL OF ZYNYZ速MAKING IT THE FIRST AND ONLY APPROVED FIRST-LINE TREATMENT FORADVANCED ANAL CANCER PATIENTS IN THE UNITED STATESSource...",
    "url": "https://finnhub.io/api/news?id=437ff194a627993c53577251cad9419e1f00060cfe44177387ae35c622e283be",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747321036,
      "headline": "Incyte Announces FDA Approval Of Zynyz For Treatment Of Advanced Anal Cancer",
      "id": 134483316,
      "image": "",
      "related": "INCY",
      "source": "Finnhub",
      "summary": "Incyte Corp: * INCYTE ANNOUNCES FDA APPROVAL OF ZYNYZ速MAKING IT THE FIRST AND ONLY APPROVED FIRST-LINE TREATMENT FORADVANCED ANAL CANCER PATIENTS IN THE UNITED STATESSource...",
      "url": "https://finnhub.io/api/news?id=437ff194a627993c53577251cad9419e1f00060cfe44177387ae35c622e283be"
    }
  }
]